What Do Allergy Shots Help With? Every Condition SCIT Treats (and Doesn't)

Yes — seasonal allergies (allergic rhinitis triggered by pollen from grasses, trees, or weeds) have the strongest evidence base for allergy shot effectiveness. The Cochrane review by Calderon et al. (2007), synthesizing 51 randomized controlled trials in 2,871 patients, found significant reductions in both symptom severity (SMD -0.73) and rescue medication use (SMD -0.57) versus placebo. Grass pollen allergy has the most robust evidence, with the Durham 1999 NEJM trial demonstrating that benefits persist at least 3 years after stopping a 3- to 4-year treatment course. Most patients with moderate-to-severe seasonal allergic rhinitis experience significant symptom reduction after completing the full treatment course.

Yes — dust mite allergy (house dust mite or HDM allergy) is one of the most well-evidenced indications for allergy shots. A Cochrane systematic review specifically for perennial allergens like HDM found symptom score SMD -0.95 and medication score SMD -1.88 — the strongest perennial evidence of any allergen. SCIT may have a slight efficacy advantage over SLIT drops for HDM in some network meta-analyses. Long-term data show approximately 55% of patients treated with depot HDM SCIT were asymptomatic at 10-year post-treatment follow-up. Concurrent environmental controls (allergen-impermeable mattress covers, HEPA filtration) significantly enhance SCIT outcomes for dust mite allergy.

Allergy shots help with cat allergy with moderate evidence — studies using the therapeutic 15-microgram Fel d 1 maintenance dose show approximately 60 to 72% symptom reduction during cat exposure challenges. The Varney 1997 trial showed cat SCIT reduced symptom scores from 61.6 to 17.1 (P less than 0.001) versus no change on placebo. Dog allergy has weaker evidence because US dog extracts are not standardized and Can f 1 content varies more than 100-fold between commercial preparations, making consistent therapeutic dosing difficult. EAACI guidelines give cat SCIT a conditional recommendation due to smaller RCT sample sizes. Both cat and dog SCIT can help, but the evidence is less definitive than for grass pollen or dust mites.

Yes — for select patients with atopic dermatitis (eczema) whose disease is driven by specific aeroallergen sensitization, allergy shots show Grade B evidence of benefit. A 2023 systematic review and meta-analysis by Chu et al. (JACI 2023, 23 RCTs, 1,957 patients) found that AIT importantly improves atopic dermatitis severity and quality of life with moderate certainty. This benefit appears primarily in patients with demonstrated IgE sensitization to aeroallergens — particularly house dust mite. Atopic dermatitis SCIT is not first-line therapy, and SCIT is not effective for atopic dermatitis without an aeroallergen IgE component. A board-certified allergist can assess whether your eczema has an aeroallergen driver that might respond to immunotherapy.

Standard allergy shots (SCIT) do not treat food allergies. SCIT is designed for IgE-mediated aeroallergen allergies and uses inhaled allergen proteins as its targets. Food allergies require oral immunotherapy (OIT), which delivers the food allergen protein by mouth in graduated doses. Palforzia (peanut OIT) received FDA approval in 2020. There is one indirect benefit worth noting: for patients with pollen-food allergy syndrome (oral allergy syndrome), treating the primary pollen sensitization with SCIT may reduce cross-reactive oral symptoms to certain raw fruits and vegetables like apples, peaches, and hazelnuts — because these foods contain proteins structurally similar to birch pollen proteins.

Allergy shots do not help with non-allergic rhinitis (triggered by irritants, temperature, hormones, or autonomic dysfunction without IgE sensitization), food allergies, drug allergies, chronic idiopathic urticaria without confirmed IgE triggers, non-allergic asthma, or contact dermatitis. Cockroach allergy SCIT failed its primary clinical endpoint in the CRITICAL 2024 trial (JACI 2024), so cockroach is effectively in the 'insufficient evidence' category. Latex SCIT exists in investigational protocols but is not standard of care. Mold SCIT has evidence only for Alternaria — other molds (Aspergillus, Cladosporium) have little to no robust clinical evidence. Identifying these boundaries is as important as knowing what SCIT does help, to avoid years of treatment for a non-responsive condition.

Yes — allergic conjunctivitis (eye allergies) improves alongside rhinitis in most allergy shot trials, because the two conditions share the same IgE-mediated mechanism and the same allergen triggers. Most major SCIT trials use 'allergic rhinoconjunctivitis' as their primary endpoint, explicitly including eye symptoms in their outcome measures. Calderon et al.'s Cochrane review and multiple EAACI systematic reviews all document improvement in both nasal and ocular symptoms. For patients whose predominant complaint is itchy, watery, or red eyes from pollen or dust mite exposure, allergy shots targeting the causal allergen typically improve both nasal and ocular symptoms simultaneously.